Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: The Mayo Clinic experience

Gut

Volumn 62, Issue 11, 2013, Pages 1607-1615

  Hart, Phil A ^a   Topazian, Mark D ^a   Witzig, Thomas E ^a   Clain, Jonathan E ^a   Gleeson, Ferga C ^a   Klebig, Robin R ^a   Levy, Michael J ^a   Pearson, Randall K ^a   Petersen, Bret T ^a   Smyrk, Thomas C ^a   Sugumar, Aravind ^a   Takahashi, Naoki ^a   Vege, Santhi S ^a   Chari, Suresh T ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; DIPHENHYDRAMINE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN G; MERCAPTOPURINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PARACETAMOL; PREDNISONE; RITUXIMAB; STEROID;

ADULT; AGED; ARTICLE; AUTOIMMUNE PANCREATITIS; BACTEREMIA; BONE MARROW SUPPRESSION; BRONCHIOLITIS; CHILL; COMBINATION CHEMOTHERAPY; COMPARATIVE EFFECTIVENESS; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDICATION; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; HYPERTRANSAMINASEMIA; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOMODULATION; INFECTION; LUNG INFILTRATE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PANCREATICODUODENECTOMY; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RECURRENT DISEASE; RETROPERITONEAL FIBROSIS; TREATMENT DURATION; VOMITING;

AUTOIMMUNE BILIARY DISEASE; CHRONIC PANCREATITIS; PANCREAS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; AUTOIMMUNE DISEASES; CHOLANGITIS, SCLEROSING; DRUG EVALUATION; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PANCREATITIS, CHRONIC; PREDNISONE; RECURRENCE; REMISSION INDUCTION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84885579114     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2012-302886     Document Type: Article

References (20)

1. Umehara H, Okazaki K, Masaki Y, et al. A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details. Mod Rheumatol 2012;22:1-14.
2. Kamisawa T, Shimosegawa T, Okazaki K, et al. Standard steroid treatment for autoimmune pancreatitis. Gut 2009;58:1504-7.
3. Sandanayake NS, Church NI, Chapman MH, et al. Presentation and management of post-treatment relapse in autoimmune pancreatitis/immunoglobulin G4-associated cholangitis. Clin Gastroenterol Hepatol 2009;7:1089-96.
4. Zamboni G, Luttges J, Capelli P, et al. Histopathological features of diagnostic and clinical relevance in autoimmune pancreatitis: a study on 53 resection specimens and 9 biopsy specimens. Virchows Archiv 2004;445:552-63. (Pubitemid 40104530)
5. Sah RP, Chari ST, Pannala R, et al. Differences in clinical profile and relapse rate of type 1 versus type 2 autoimmune pancreatitis. Gastroenterology 2010;139: 140-8; quiz e12-3.
6. Ryu JK, Chung JB, Park SW, et al. Review of 67 patients with autoimmune pancreatitis in Korea: a multicenter nationwide study. Pancreas 2008;37: 377-85.
7. Ghazale A, Chari ST, Zhang L, et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology 2008;134:706-15. (Pubitemid 351312724)
8. Raina A, Yadav D, Krasinskas AM, et al. Evaluation and management of autoimmune pancreatitis: experience at a large US center. Am J Gastroenterol 2009;104:2295-306.
9. Witzig TE, Inwards DJ, Habermann TM, et al. Treatment of benign orbital pseudolymphomas with the monoclonal anti-CD20 antibody rituximab. Mayo Clin Proc 2007;82:692-9. (Pubitemid 46878092)
10. Plaza JA, Garrity JA, Dogan A, et al. Orbital inflammation with IgG4-positive plasma cells: manifestation of IgG4 systemic disease. Arch Ophthalmol 2011;129:421-8.
11. Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med 2012;366:539-51.
12. Ahmed AR, Spigelman Z, Cavacini LA, et al. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 2006;355:1772-9. (Pubitemid 44631360)
13. Topazian M, Witzig TE, Smyrk TC, et al. Rituximab therapy for refractory biliary strictures in immunoglobulin G4-associated cholangitis. Clin Gastroenterol Hepatol 2008;6:364-6. (Pubitemid 351318380)
14. Shimosegawa T, Chari ST, Frulloni L, et al. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. Pancreas 2011;40:352-8.
15. Chari ST, Smyrk TC, Levy MJ, et al. Diagnosis of autoimmune pancreatitis: the Mayo Clinic experience. Clin Gastroenterol Hepatol 2006;4:1010-16; quiz 934. (Pubitemid 44118845)
16. Peerzada MM, Spiro TP, Daw HA. Pulmonary toxicities of biologics: a review. Anticancer Drugs 2010;21:131-9.
17. Khosroshahi A, Carruthers MN, Deshpande V, et al. Rituximab for the treatment of IgG4-related disease: lessons from 10 consecutive patients. Medicine 2012;91:57-66.
18. Su C, Lichtenstein GR. Treatment of inflammatory bowel disease with azathioprine and 6-mercaptopurine. Gastroenterol Clin North Am 2004;33:209-34, viii. (Pubitemid 38737268)
19. Keystone E, Fleischmann R, Emery P, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 2007;56:3896-908. (Pubitemid 350262316)
20. Tobinai K, Igarashi T, Itoh K, et al. Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non-Hodgkin lymphoma mostly pretreated with rituximab: a multicenter phase II study. Cancer Sci 2011;102:1698-705.